Ligand Pharmaceuticals (LGND) Long-Term Deferred Tax (2011 - 2026)

Ligand Pharmaceuticals has disclosed Long-Term Deferred Tax across 15 years of filings, most recently posting $8.5 million for Q1 2026.

• Long-Term Deferred Tax for Q1 2026 came in at $8.5 million, up 1451.83% year-over-year; the trailing twelve-month figure through Mar 2026 was $8.5 million (up 1451.83% YoY), and the FY2025 annual result was $8.3 million, up 11490.28% from the prior year.
• Long-Term Deferred Tax came in at $8.5 million for Q1 2026 at Ligand Pharmaceuticals, up from $8.3 million in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $35.7 million in Q1 2022 to a low of $72000.0 in Q4 2024.
• The 5-year median for Long-Term Deferred Tax is $8.4 million (2025), against an average of $10.1 million.
• Across the five-year window, Long-Term Deferred Tax slumped 99.09% in 2024 and surged 12112.82% in 2025, its largest moves.
• Ligand Pharmaceuticals' Long-Term Deferred Tax stood at $8.5 million in 2022, then plunged by 97.49% to $214000.0 in 2023, then sank by 66.36% to $72000.0 in 2024, then surged by 11490.28% to $8.3 million in 2025, then gained by 1.53% to $8.5 million in 2026.
• The last three Long-Term Deferred Tax figures came in at $8.5 million (Q1 2026), $8.3 million (Q4 2025), and $9.5 million (Q3 2025), per Business Quant data.